Table 1.
Registered clinical trials of matricellular protein-based therapeutic agents
| Family | Agent | Trial Design | Population | Study Phase | Enrollment (actual or estimated) | Trial Number |
|---|---|---|---|---|---|---|
| Thrombospondins | ABT-510 | TSP-1 mimetic to treat advanced renal cell carcinoma | Patients with locally recurrent or metastatic renal cell carcinoma that is not amendable to curative resection | Phase II | 103 | NCT00073125 |
| ABT-510 | TSP-1 mimetic to treat advanced or metastatic soft tissue carcinoma | Patients with locally advanced or metastatic soft tissue sarcoma not amenable to surgery, radiotherapy or combined modality therapy with curative intent | Phase II | 88 | NCT00061659 | |
| ABT-510 | TSP-1 mimetic plus combination chemotherapy in subjects with non-small cell lung cancer | Patients with Stage IIIB with pleural effusion or Stage IV NSCLC | Phase II | 25 | NCT00061646 | |
| ABT-510 | TSP-1 mimetic to treat patients with advanced head and neck cancer | Patients with squamous cell carcinoma of the head and neck that is not amenable to curative therapy, including radiation or surgery | Phase I, II | 6 | NCT00113334 | |
| ABT-510 | TSP-1 mimetic to treat subjects with refractory lymphoma | Patients with non-Hodgkin's Lymphoma (NHL) (excluding Burkitt's, Burkitt's type or HIV associated lymphoma) or Hodgkin's Lymphoma (HL) that is refractory to or has relapsed after standard therapy or for which there is no known effective treatment | Phase II | 67 | NCT00061672 | |
| CVX-045 | A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors | Patients with advanced solid tumors unresponsive to currently available therapies, or for which there is no standard therapy | Phase I | 40 | NCT00879554 | |
|
| ||||||
| Osteopontin | Osteopontin | Osteopontin addition to formula to increase infant growth, health, and immune function | Healthy infants 37–42 weeks of age. | 320 | NCT00970398 | |
|
| ||||||
| Tenascins | Neuradiab® | Combination therapy with Bevacizumab and Neuradiab (131I-labled anti tenascin mab) | Recurrent glioblastoma | Phase II | 60 | NCT00906516 |
| 211At labled 81C6 (mab) | Astatine 211 labled anti-tenascin mab (At 211 Mab 81C6) delivered into the resection cavity | Recurrent primary and metastatic brain tumors | Phase I, II | 12–24 | NCT00003461 | |
| I 131 Mab 81C6 | Iodine 131 labled anti-tenascin mab infused into the resection cavity and followed by carmustine and irinotecan chemotherapy | Primary brain tumors after external beam radiation | Phase I, II | 21 | NCT00003484 | |
| I 131 Mab 81C6 | Iodine 131 labled anti-tenascin mab infused into the resection cavity | Primary or metastatic brain tumors, with or without previous radiotherapy | Phase I, II | NCT00002752 | ||
| I 131 Mab 81C6 | Comparison of bolus injection and microinfusion of radiolabled anti-tenascin mab | Malignant primary brain tumors | Phase I, II | 10 | NCT00003478 | |
| I 131 Mab 81C6 | Intracystic delivery of radiolabled anti-tenascin mab | Recurrent cycstic glioma | Phase I | 6 | NCT00002753 | |
| Neuradiab® | Randomized evaluation of radiolabled anti-tenascin mab in combination with radiation therapy (XRT) and temozolomide | Newly diagnosed glioblastoma multiforme | Phase III | 9 | NCT00615186 | |
|
| ||||||
| CCNs | FG-3019 | Monoclonal antibody targeting CTGF for treatment of liver fibrosis | Chronic hepatitis B infection and liver fibrosis | Phase II | 228 | NCT01217632 |
| FG-3019 | Monoclonal antibody targeting CTGF for treatment of advanced or metastatic pancreatic cancer | Stage III or IV adenocarcinoma of the pancreas | Phase I | 50 | NCT01181245 | |
| FG-3019 | Monoclonal antibody targeting CTGF for treatment of focal segmental glomerulosclerosis | Focal segmental glomerulosclerosis | Phase I | 12 | NCT00782561 | |
| FG-3019 | Monoclonal antibody targeting CTGF for treatment of diabetic nephropathy | Diabetic nephropathy and proteinuria (with ACE inhibitor or angiotensin II receptor antagonist therapy) | Phase I | 36 | NCT00754143 | |
| Phase II | 34 | NCT00913393 | ||||
| FG-3019 | Monoclonal antibody targeting CTGF for treatment of idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis | Phase II | 136 | NCT01890265 | |
| Phase II | 42 | NCT01262001 | ||||
| Phase I | 27 | NCT00074698 | ||||
| FG-3019 | Monoclonal antibody targeting CTGF as neoadjuvant chemotherapy for advanced pancreatic cancer | Pancreatic ductal adenocarcinoma | Phase II | 40 | NCT02210559 | |
| FG-3019 | Monoclonal antibody targeting CTGF for treatment of incipient nephropathy | Type 1 or type 2 diabetes and incipient nephropathy | Phase I | 20 | NCT00102297 | |
| Pravastatin | Small molecule targeting Rho/ROCK/CTGF pathway for treatment of radio-induced fibrosis | Cutaneous and subcutaneous radio-induced fibrosis | Phase II | 55 | NCT01268202 | |
| Sparc | Nab-paclitaxel | Albumin bound nanoparticles proposed to target elevated SPARC in tumor microenvironment | SPARC positive patients with resectable/resectable borderline pancreatic cancer | Pilot | 15 | NCT01442974 |
|
| ||||||
| PEDF | AdGVPEDF.11D | Adenoviral vector containg the gene to encode PEDF | Neovascular age-related macular degeneration (AMD) | Phase I | NCT00109499 | |
Selected clinical trials from the U.S. National Institutes of Health database, ClinicalTrials.gov